公开(公告)号：US20220056125A1

公开(公告)日：2022-02-24

申请号：US17405275

申请日：2021-08-18

Applicant: Cephalon, Inc.

Inventor： Anna Mikaela BRACKEN ,  Adam CLARKE ,  Bridget A. COOKSEY ,  Anthony Gerard DOYLE ,  Mark Terence LIDDAMENT ,  Matthew POLLARD ,  Lynn POULTON ,  Anna Maria Matilda QUIGLEY ,  Julia ROZENFELD ,  Marta SZABAT

IPC: C07K16/28 ,  A61P35/04 ,  A61P17/10 ,  A61P29/00

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human PAR-2 and compositions comprising such antibodies or antigen-binding fragments thereof. In a particular aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human PAR-2 block the interaction between a PAR-2 activating ligand and an extracellular domain of PAR-2, and/or blocks PAR-2 activation by a PAR-2 activating ligand, In further aspects, the antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with increased expression of PAR-2 and/or diseases or conditions that can be alleviated by antagonizing activation of PAR-2 by a PAR-2 activating ligand (e.g., airway diseases, skin diseases, cancer, orofacial granulomatosis, inflammatory conditions, and pain associated with various diseases or conditions).

公开(公告)号：US20210355205A1

公开(公告)日：2021-11-18

申请号：US17385532

申请日：2021-07-26

Applicant: Cephalon, Inc.

Inventor： Mark Terence Liddament ,  Anthony Doyle ,  Adam Clarke ,  David Jose Simon Laine ,  Bridget Ann Cooksey

IPC: C07K16/24 ,  A61P37/08

Abstract: Disclosed herein are fully human antibody molecules that immunospecifically bind to human IL-5. The antibody molecules can bind to human IL-5 with an equilibrium affinity constant (KD) of at least about 40 pM as determined by surface plasmon resonance.

公开(公告)号：US20200040089A1

公开(公告)日：2020-02-06

申请号：US16527354

申请日：2019-07-31

Applicant: Cephalon, Inc.

Inventor： Doris Shim Siew Chen ,  Lynn Dorothy Poulton ,  Adam Clarke ,  David Jose Simon Laine ,  Matthew Pollard ,  Bridget Ann Cooksey ,  Anthony Doyle ,  Jason William Gill

IPC: C07K16/28 ,  A61P11/00

Abstract: Disclosed herein are human antibody molecules that immunospecifically bind to human CXCR2. The disclosed human antibody molecules are potent and selective antagonists of CXCR2 functions and prevent the recruitment of neutrophils into tissues without strongly depleting circulating neutrophil numbers. Pharmaceutical compositions, nucleic acid molecules, vectors, cells, and uses of the disclosed antibodies are also provided.

公开(公告)号：US20180327351A1

公开(公告)日：2018-11-15

申请号：US15756692

申请日：2016-09-08

Applicant: CEPHALON, INC.

Inventor： Ralph LAUFER ,  Gregory R. OTT

IPC: C07C271/22 ,  C07C229/42 ,  C07C237/20 ,  C07F9/09 ,  C07C305/12 ,  C07D263/18 ,  C07K4/00 ,  C07D223/16 ,  C07D207/09 ,  C07C233/36 ,  C07C233/05 ,  C07C311/51 ,  C07C233/47 ,  C07H13/04 ,  C07C233/54 ,  C07C271/28 ,  A61K31/198 ,  A61K31/325 ,  A61K31/196 ,  A61K31/661 ,  A61K31/255 ,  A61K31/421 ,  A61K38/03 ,  A61K31/216 ,  A61K31/24 ,  A61K31/55 ,  A61K31/40 ,  A61K31/165 ,  A61K31/18 ,  A61K31/7028

CPC classification number: C07C271/22 ,  A61K31/165 ,  A61K31/18 ,  A61K31/196 ,  A61K31/198 ,  A61K31/216 ,  A61K31/24 ,  A61K31/255 ,  A61K31/325 ,  A61K31/40 ,  A61K31/421 ,  A61K31/55 ,  A61K31/661 ,  A61K31/7028 ,  A61K38/03 ,  C07C229/42 ,  C07C233/05 ,  C07C233/36 ,  C07C233/47 ,  C07C233/51 ,  C07C233/54 ,  C07C237/20 ,  C07C271/28 ,  C07C305/12 ,  C07C311/51 ,  C07D207/08 ,  C07D207/09 ,  C07D223/12 ,  C07D223/16 ,  C07D263/18 ,  C07F9/09 ,  C07H13/04 ,  C07K4/00

Abstract: The present disclosure relates to prodrugs of 7-chlorokynurenic acid. In certain embodiments, the prodrugs include those having the structure of any one of formula (I)-(VIII), wherein R1-R13, monomer 1, monomer 2, and linker are defined herein. Also provided are methods of preparing and using these prodrugs.

公开(公告)号：US10039750B2

公开(公告)日：2018-08-07

申请号：US15359777

申请日：2016-11-23

Applicant: Cephalon, Inc.

Inventor： Martin Ian Cooper ,  Laurent D. Courvoisier ,  Mark Eddleston ,  Robert E. McKean

IPC: A61K31/4184 ,  A61K9/00 ,  A61K47/26 ,  A61K9/14 ,  A61K9/19 ,  C07D235/16

CPC classification number: A61K31/4184 ,  A61K9/0019 ,  A61K9/14 ,  A61K9/19 ,  A61K47/26 ,  C07D235/16

Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.

公开(公告)号：US20180056018A1

公开(公告)日：2018-03-01

申请号：US15689299

申请日：2017-08-29

Applicant: Cephalon, Inc.

Inventor： Janice M.G. Canvin ,  Marla D. Curran ,  Robert B. Noble ,  Saku JP Torvinen ,  James Zangrilli

IPC: A61M16/00 ,  A61M15/00 ,  A61M16/14 ,  G06F19/00 ,  C07K16/28

CPC classification number: A61M16/024 ,  A61K2039/505 ,  A61K2039/544 ,  A61M15/009 ,  A61M16/026 ,  A61M16/14 ,  A61M2016/0018 ,  A61M2016/0027 ,  A61M2202/064 ,  A61M2205/3553 ,  A61M2205/3592 ,  A61M2205/502 ,  A61M2205/505 ,  A61M2205/583 ,  A61M2205/584 ,  A61M2205/8206 ,  A61M2230/40 ,  C07K16/244 ,  C07K16/2866 ,  G06F19/325 ,  G06F19/3456 ,  G16H10/20 ,  G16H20/13 ,  G16H50/20

Abstract: Digital systems, devices and methods for managing a drug therapy, such as an anti-IL5 mAb or anti-IL5 receptor mAb treatment regimen for patients suffering from severe asthma (e.g., eosinophilic asthma), are provided. The digital systems, devices and methods may include hardware and software for predicting patient responses to a long term anti-IL5 mAb or anti-IL5 receptor mAb treatment based on clinical data obtained following an initial treatment period.

公开(公告)号：US20170267683A1

公开(公告)日：2017-09-21

申请号：US15529883

申请日：2015-11-25

Applicant: CEPHALON, INC.

Inventor： Stephen J. BIERLMAIER ,  Ralph C. HALTIWANGER ,  Martin J. JACOBS

IPC: C07D487/04 ,  C07C57/15 ,  C07C59/245 ,  C07D207/28 ,  C07C59/06 ,  C07C53/10

CPC classification number: C07D487/04 ,  C07B2200/13 ,  C07C53/10 ,  C07C57/15 ,  C07C59/06 ,  C07C59/245 ,  C07D207/28

Abstract: The present disclosure relates to crystalline forms of 4,5,6,7-tetrahydro-11-methoxy-2-[(4-methyl-1-piperazinyl)methyl]-1H-cyclopenta[a]pyrrolo[3,4-c]carbazole-1,3(2H)-dione, including salts forms and free base forms.

公开(公告)号：US20170173017A1

公开(公告)日：2017-06-22

申请号：US15451960

申请日：2017-03-07

Applicant: Cephalon, Inc.

Inventor： Shawn P. Allwein ,  Laurent Courvoisier (deceased) ,  Martin J. Jacobs ,  Gregory R. Ott

IPC: A61K31/506

CPC classification number: A61K31/506 ,  C07D403/04 ,  C07D403/12

Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.

公开(公告)号：US20170081400A1

公开(公告)日：2017-03-23

申请号：US15267213

申请日：2016-09-16

Applicant: Cephalon, Inc.

Inventor： Lynn Dorothy Poulton ,  Matthew Pollard ,  Anthony G. Doyle ,  Bridget Ann Cooksey ,  Vanya Pande ,  Adam William Clarke

IPC: C07K16/24

CPC classification number: C07K16/241 ,  A61K2039/505 ,  A61P11/06 ,  A61P37/06 ,  C07K16/2875 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.

公开(公告)号：US09440984B2

公开(公告)日：2016-09-13

申请号：US14944668

申请日：2015-11-18

Applicant: Cephalon, Inc.

Inventor： Ralph C. Haltiwanger ,  Eugen F. Mesaros ,  Gregory R. Ott

IPC: C07D487/04 ,  A61K31/53

CPC classification number: C07D487/04 ,  A61K31/53

Abstract: This application provides compounds of the general formula (I) and/or a salt thereof, where X, R1 and R2 are as defined herein. Compositions and therapeutic uses are also described.